EN
Select language

Bracco Group profile

Bracco is an international Group active in the healthcare sector and a leader in diagnostic imaging. It has around 3,420 employees and annual total consolidated revenues of around 1,29 billion euros, 86% of which from international sales. In the Research and Development area, the company invests approximately 9% of reference turnover in the imaging diagnostics and medical devices sectors and has a portfolio comprising over 2,000 patents.

Bracco’s commitment to diagnostic imaging began in the 1950’s and obtained the first results at the start of the 1960’s, with the development of the first contrast agent to improve image quality in radiographic procedures: iodamide. The following years saw a redoubling of efforts in R&D, and resulted in the development of a highly innovative contrast agent, iopamidol, which allowed for dramatically improved tolerability and safety during radiographic, vascular and CT procedures. Launched at the beginning of the 1980’s, it is still today the go-to product for the entire international scientific community. Other significant Bracco research achievements include the development of a contrast medium for MRI procedures based on gadobenate dimeglumine, introduced in 1998, and a contrast agent for ultrasound examinations based on microbubble with sulfur hexafluoride gas, made available in 2001. Both of these products represented a significant step forward in terms of what was available on the market at the time. Later, Bracco’s product portfolio was further enhanced by other contrast agents for CT scans, MRI and by medical devices to optimize the administration of contrast media in different imaging modalities. In October, 2017 Bracco acquired SurgVision, a high-tech innovative start-up company specialized in developing a real-time Fluorescence Image Guided Surgery platform combining a targeted imaging agent and a device for efficient tumor visualization during oncology surgical procedures. In 2019 Bracco Imaging also enriched its product portfolio by expanding the range of oncology nuclear imaging solutions in the urology in the Urology segment and other specialties with the acquisition of Blue Earth Diagnostics. The company is active in molecular imaging with innovative agents for positron emission tomography (PET) in patients with suspected recurrent prostate cancer.

Bracco contrast media are sold in over 100 countries, both directly and indirectly through branches, joint ventures and licence and distribution agreements. Thanks to the quality and reliability of its products, the Group boasts leading positions in the most important geographical areas such as North America, Europe and Japan.

Research and Development activities are concentrated in the laboratories in Geneva and Lausanne (Switzerland), Monroe and Silicon Valley (United States) and Italy (Colleretto Giacosa). Each research centre has specialised experience and expertise at the absolute cutting edge in different imaging modalities and operates in synergy with the medical and regulatory departments, whose operations are located in Milan (Italy), Konstanz (Germany), Paris (France), Monroe and Long Island (United States), Montreal (Canada), Mexico City (Mexico), São Paulo (Brazil), Beijing (China), and Tokyo (Japan).

Thanks to constant investment in operating processes, Bracco Imaging has reached levels of excellence in quality, in full compliance with all applicable regulations in every country where it operates, and with special attention paid to ecologically sustainable production. The production activities of Bracco Imaging are carried out in Italy (Ceriano Laghetto, Torviscosa and Colleretto Giacosa), Canada (Montreal), Switzerland (Geneva), Germany (Singen), Japan (Saitama) and China (Shanghai).

The Bracco diagnostic imaging product portfolio is completed by several medical devices and advanced administration systems for contrast imaging products in the fields of cardiology and radiology, developed by Acist Medical Systems. The company, which was acquired by the Bracco Group in 2001, has its corporate headquarters, manufacturing and R&D facilities in Minneapolis, Minnesota (USA), with regional offices in Europe and Asia. Its advanced systems are used in over 40 countries in the most world-renowned centres. More than 15 million people around the world have had cardiovascular angiographic procedures using an ACIST system.

Another important area of activity for the Bracco Group regards the healthcare services provided by the Italian Diagnostics Centre, a polyclinic based in Milan. With 24 satellite units in the city and in Lombardy, the CDI offers different services of prevention, diagnosis, rehabilitation and personalized treatment, with a focus on radiosurgery and day-surgery. With 40 years experience, it offers a wide range of services for an amount per year of 150,000 diagnostic procedures in 50 clinical specialisations and 5 million analyses for 500 types of exams. Equipped with the very latest technological systems (such as the Cyberknife radiosurgery robot and the Ikonyscope microscope for oncologic diagnostics), the CDI is an accredited body of the Joint Commission International.

Since its foundation, Bracco has been a socially responsible company in each area of activity - in business as in every other context. The company is strongly committed to social, educational, environmental and cultural improvement and in the promotion of Gender Equality.